Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19 : Data from the SEMI-COVID-19 Registry
BACKGROUND: The impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization.
METHODS: This work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19 disease outcomes between patients receiving chronic statin therapy who maintained this therapy during hospitalization versus those who did not. Propensity score matching was used to match each statin user whose therapy was maintained during hospitalization to a statin user whose therapy was withdrawn during hospitalization.
RESULTS: After propensity score matching, continuation of statin therapy was associated with lower all-cause mortality (OR 0.67, 0.54-0.83, p < 0.001); lower incidence of acute kidney injury (AKI) (OR 0.76,0.6-0.97, p = 0.025), acute respiratory distress syndrome (ARDS) (OR 0.78, 0.69- 0.89, p < 0.001), and sepsis (4.82% vs 9.85%, p = 0.008); and less need for invasive mechanical ventilation (IMV) (5.35% vs 8.57, p < 0.001) compared to patients whose statin therapy was withdrawn during hospitalization.
CONCLUSIONS: Patients previously treated with statins who are hospitalized for COVID-19 and maintain statin therapy during hospitalization have a lower mortality rate than those in whom therapy is withdrawn. In addition, statin therapy was associated with a decreased probability that patients with COVID-19 will develop AKI, ARDS, or sepsis and decreases the need for IMV.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Drugs - 81(2021), 6 vom: 29. Apr., Seite 685-695 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|---|
| Anmerkungen: |
Date Completed 19.05.2021 Date Revised 17.03.2022 published: Print-Electronic CommentIn: Drugs. 2021 Jun;81(9):1125-1127. - PMID 34047956 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40265-021-01498-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323387020 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323387020 | ||
| 003 | DE-627 | ||
| 005 | 20231225184053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40265-021-01498-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323387020 | ||
| 035 | |a (NLM)33782908 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Torres-Peña, José David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19 |b Data from the SEMI-COVID-19 Registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2021 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Drugs. 2021 Jun;81(9):1125-1127. - PMID 34047956 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization | ||
| 520 | |a METHODS: This work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19 disease outcomes between patients receiving chronic statin therapy who maintained this therapy during hospitalization versus those who did not. Propensity score matching was used to match each statin user whose therapy was maintained during hospitalization to a statin user whose therapy was withdrawn during hospitalization | ||
| 520 | |a RESULTS: After propensity score matching, continuation of statin therapy was associated with lower all-cause mortality (OR 0.67, 0.54-0.83, p < 0.001); lower incidence of acute kidney injury (AKI) (OR 0.76,0.6-0.97, p = 0.025), acute respiratory distress syndrome (ARDS) (OR 0.78, 0.69- 0.89, p < 0.001), and sepsis (4.82% vs 9.85%, p = 0.008); and less need for invasive mechanical ventilation (IMV) (5.35% vs 8.57, p < 0.001) compared to patients whose statin therapy was withdrawn during hospitalization | ||
| 520 | |a CONCLUSIONS: Patients previously treated with statins who are hospitalized for COVID-19 and maintain statin therapy during hospitalization have a lower mortality rate than those in whom therapy is withdrawn. In addition, statin therapy was associated with a decreased probability that patients with COVID-19 will develop AKI, ARDS, or sepsis and decreases the need for IMV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Pérez-Belmonte, Luis M |e verfasserin |4 aut | |
| 700 | 1 | |a Fuentes-Jiménez, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a López Carmona, Mª Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Martinez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a López-Miranda, José |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco Sánchez, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas Núñez, Juan Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Del Corral Beamonte, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Magallanes Gamboa, Jeffrey Oskar |e verfasserin |4 aut | |
| 700 | 1 | |a González García, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a González Moraleja, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés Troncoso, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Taboada Martínez, María Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Del Fidalgo Montero, María Del Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Seguí Ripol, José Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Gil Sánchez, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Alegre González, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Boixeda, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés Rodríguez, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Ena, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a García García, Gema María |e verfasserin |4 aut | |
| 700 | 1 | |a Ventura Esteve, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Rincón, José Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Huelgas, Ricardo |e verfasserin |4 aut | |
| 700 | 0 | |a SEMI-COVID-19 Network |e verfasserin |4 aut | |
| 700 | 1 | |a Rojo, José Manuel Casas |e investigator |4 oth | |
| 700 | 1 | |a Rincón, José Manuel Ramos |e investigator |4 oth | |
| 700 | 1 | |a Bermejo, Carlos Lumbreras |e investigator |4 oth | |
| 700 | 1 | |a Núñez-Cortés, Jesús Millán |e investigator |4 oth | |
| 700 | 1 | |a Santos, Juan Miguel Antón |e investigator |4 oth | |
| 700 | 1 | |a Huelgas, Ricardo Gómez |e investigator |4 oth | |
| 700 | 1 | |a de Blas, Paloma Agudo |e investigator |4 oth | |
| 700 | 1 | |a Cañas, Coral Arévalo |e investigator |4 oth | |
| 700 | 1 | |a Ayuso, Blanca |e investigator |4 oth | |
| 700 | 1 | |a Morejón, José Bascuñana |e investigator |4 oth | |
| 700 | 1 | |a Escudero, Samara Campos |e investigator |4 oth | |
| 700 | 1 | |a Frías, María Carnevali |e investigator |4 oth | |
| 700 | 1 | |a Tejido, Santiago Cossio |e investigator |4 oth | |
| 700 | 1 | |a de Miguel Campo, Borja |e investigator |4 oth | |
| 700 | 1 | |a Pedroche, Carmen Díaz |e investigator |4 oth | |
| 700 | 1 | |a Simon, Raquel Diaz |e investigator |4 oth | |
| 700 | 1 | |a Reyne, Ana García |e investigator |4 oth | |
| 700 | 1 | |a Huerta, Lucia Jorge |e investigator |4 oth | |
| 700 | 1 | |a Blanco, Antonio Lalueza |e investigator |4 oth | |
| 700 | 1 | |a Gonzalo, Jaime Laureiro |e investigator |4 oth | |
| 700 | 1 | |a Lora-Tamayo, Jaime |e investigator |4 oth | |
| 700 | 1 | |a Bermejo, Carlos Lumbreras |e investigator |4 oth | |
| 700 | 1 | |a de la Calle, Guillermo Maestro |e investigator |4 oth | |
| 700 | 1 | |a Perpiña, Barbara Otero |e investigator |4 oth | |
| 700 | 1 | |a Ruiz, Diana Paredes |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Marcos Sánchez |e investigator |4 oth | |
| 700 | 1 | |a Montes, Javier Tejada |e investigator |4 oth | |
| 700 | 1 | |a Corbella, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Homs, Narcís |e investigator |4 oth | |
| 700 | 1 | |a Montero, Abelardo |e investigator |4 oth | |
| 700 | 1 | |a Mora-Luján, Jose María |e investigator |4 oth | |
| 700 | 1 | |a Rivas, Manuel Rubio |e investigator |4 oth | |
| 700 | 1 | |a Casas, Laura Abarca |e investigator |4 oth | |
| 700 | 1 | |a de Oña, Álvaro Alejandre |e investigator |4 oth | |
| 700 | 1 | |a Beato, Rubén Alonso |e investigator |4 oth | |
| 700 | 1 | |a Gonzalo, Leyre Alonso |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Jaime Alonso |e investigator |4 oth | |
| 700 | 1 | |a Oblitas, Crhistian Mario Amodeo |e investigator |4 oth | |
| 700 | 1 | |a García, Cristina Ausín |e investigator |4 oth | |
| 700 | 1 | |a Cebrián, Marta Bacete |e investigator |4 oth | |
| 700 | 1 | |a Corral, Jesús Baltasar |e investigator |4 oth | |
| 700 | 1 | |a Guerrero, Maria Barrientos |e investigator |4 oth | |
| 700 | 1 | |a Estrada, Alejandro Bendala |e investigator |4 oth | |
| 700 | 1 | |a Moreno, María Calderón |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Paula Carrascosa |e investigator |4 oth | |
| 700 | 1 | |a Carrillo, Raquel |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Sabela Castañeda |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Eva Cervilla |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Agustín Diego Chacón |e investigator |4 oth | |
| 700 | 1 | |a Carvajal, Maria Carmen Cuenca |e investigator |4 oth | |
| 700 | 1 | |a de Santos, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Gómez, Andrés Enríquez |e investigator |4 oth | |
| 700 | 1 | |a Carracedo, Eduardo Fernández |e investigator |4 oth | |
| 700 | 1 | |a Jenaro, María Mercedes Ferreiro-Mazón |e investigator |4 oth | |
| 700 | 1 | |a Valle, Francisco Galeano |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Alejandra |e investigator |4 oth | |
| 700 | 1 | |a Fernandez-Bravo, Irene Garcia |e investigator |4 oth | |
| 700 | 1 | |a Leoni, María Eugenia García |e investigator |4 oth | |
| 700 | 1 | |a Antunez, Maria Gomez |e investigator |4 oth | |
| 700 | 1 | |a Narciso, Candela González San |e investigator |4 oth | |
| 700 | 1 | |a Gurjian, Anthony Alexander |e investigator |4 oth | |
| 700 | 1 | |a Ibáñez, Lorena Jiménez |e investigator |4 oth | |
| 700 | 1 | |a Olleros, Cristina Lavilla |e investigator |4 oth | |
| 700 | 1 | |a Mendo, Cristina Llamazares |e investigator |4 oth | |
| 700 | 1 | |a García, Sara Luis |e investigator |4 oth | |
| 700 | 1 | |a Jimeno, Víctor Mato |e investigator |4 oth | |
| 700 | 1 | |a Nohales, Clara Millán |e investigator |4 oth | |
| 700 | 1 | |a Núñez-Cortés, Jesús Millán |e investigator |4 oth | |
| 700 | 1 | |a Ledesma, Sergio Moragón |e investigator |4 oth | |
| 700 | 1 | |a Miguez, Antonio Muiño |e investigator |4 oth | |
| 700 | 1 | |a Delgado, Cecilia Muñoz |e investigator |4 oth | |
| 700 | 1 | |a Ortega, Lucía Ordieres |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Susana Pardo |e investigator |4 oth | |
| 700 | 1 | |a Virto, Alejandro Parra |e investigator |4 oth | |
| 700 | 1 | |a Sanz, María Teresa Pérez |e investigator |4 oth | |
| 700 | 1 | |a Llorente, Blanca Pinilla |e investigator |4 oth | |
| 700 | 1 | |a Ruiz, Sandra Piqueras |e investigator |4 oth | |
| 700 | 1 | |a Fernández-Llamazares, Guillermo Soria |e investigator |4 oth | |
| 700 | 1 | |a Macías, María Toledano |e investigator |4 oth | |
| 700 | 1 | |a Samaniego, Neera Toledo |e investigator |4 oth | |
| 700 | 1 | |a do Rego, Ana Torres |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Maria Victoria Villalba |e investigator |4 oth | |
| 700 | 1 | |a Villarreal, Gracia |e investigator |4 oth | |
| 700 | 1 | |a Etayo, María Zurita |e investigator |4 oth | |
| 700 | 1 | |a Troncoso, Jorge Álvarez |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Francisco Arnalich |e investigator |4 oth | |
| 700 | 1 | |a Quintana, Francisco Blanco |e investigator |4 oth | |
| 700 | 1 | |a Arenzana, Carmen Busca |e investigator |4 oth | |
| 700 | 1 | |a Molina, Sergio Carrasco |e investigator |4 oth | |
| 700 | 1 | |a Candalija, Aranzazu Castellano |e investigator |4 oth | |
| 700 | 1 | |a Bengoa, Germán Daroca |e investigator |4 oth | |
| 700 | 1 | |a de Gea Grela, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a de Lorenzo Hernández, Alicia |e investigator |4 oth | |
| 700 | 1 | |a Vidal, Alejandro Díez |e investigator |4 oth | |
| 700 | 1 | |a Capitán, Carmen Fernández |e investigator |4 oth | |
| 700 | 1 | |a Iglesias, Maria Francisca García |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Borja González |e investigator |4 oth | |
| 700 | 1 | |a Gil, Carmen Rosario Herrero |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Juan María Herrero |e investigator |4 oth | |
| 700 | 1 | |a Hontañón, Víctor |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d 1976 |g 81(2021), 6 vom: 29. Apr., Seite 685-695 |w (DE-627)NLM00001611X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2021 |g number:6 |g day:29 |g month:04 |g pages:685-695 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40265-021-01498-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2021 |e 6 |b 29 |c 04 |h 685-695 | ||